IL-5 and TNF-α participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis

被引:75
作者
Lampinen, M
Carlson, M
Sangfelt, P
Taha, Y
Thörn, M
Lööf, L
Raab, Y
Venge, P
机构
[1] Univ Uppsala, Dept Med Sci, Inflammat Res Lab, Uppsala, Sweden
[2] Univ Uppsala, Dept Surg, Uppsala, Sweden
关键词
ulcerative colitis; inflammatory bowel disease; eosinophil; migration; cytokine;
D O I
10.1023/A:1010659803912
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
There is an increased influx of activated eosinophils to the intestinal mucosa in active ulcerative colitis, and an increased release of eosinophil-derived proteins, such as ECP, has also been observed. These findings indicate that eosinophils may contribute to tissue damage and intestinal inflammation in this disease. The relative importance of different chemotactic factors and the impact of steroid treatment on their effect in active ulcerative colitis are not known. We measured the eosinophil chemotactic activity in perfusion fluids from 11 patients with ulcerative colitis before and after steroid treatment and from 7 control patients. The effect of neutralizing antibodies to IL-5 and -8, RANTES, eotaxin, MCP-3, TNF-alpha, GM-CSF was investigated. The chemotactic activity was higher in perfusion fluids from patients than from controls (P = 0.0043). Anti-IL-5 (P = 0.005) and -TNF-alpha (P = 0.017) inhibited the activity in perfusion fluids obtained before treatment. Steroid treatment prevented the effect of all antibodies but had no significant effect on the chemotactic activity. The chemotactic activity correlated with the levels of eosinophil granule proteins in the perfusion fluids. In conclusion, in ulcerative colitis, eosinophils are attracted to the intestinal tissue by chemotactic factors, of which IL-5 and TNF-alpha may be the most prominent steroid-sensitive ones. The steroid-insensitive chemotactic activities remain unidentified.
引用
收藏
页码:2004 / 2009
页数:6
相关论文
共 32 条
[1]   Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis [J].
Baert, FJ ;
D'Haens, GR ;
Peeters, M ;
Hiele, MI ;
Schaible, TF ;
Shealy, D ;
Geboes, K ;
Rutgeerts, PJ .
GASTROENTEROLOGY, 1999, 116 (01) :22-28
[2]   Mast cells are an important cellular source of tumour necrosis factor α in human intestinal tissue [J].
Bischoff, SC ;
Lorentz, A ;
Schwengberg, S ;
Weier, G ;
Raab, R ;
Manns, MP .
GUT, 1999, 44 (05) :643-652
[3]   Mucosal allergy: Role of mast cells and eosinophil granulocytes in the gut [J].
Bischoff, SC .
BAILLIERES CLINICAL GASTROENTEROLOGY, 1996, 10 (03) :443-459
[4]   Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease [J].
Bischoff, SC ;
Wedemeyer, J ;
Herrmann, A ;
Meier, PN ;
Trautwein, C ;
Cetin, Y ;
Maschek, H ;
Stolte, M ;
Gebel, M ;
Manns, MP .
HISTOPATHOLOGY, 1996, 28 (01) :1-13
[5]   Cytokines induce selective granulocyte chemotactic responses [J].
Bittleman, DB ;
Erger, RA ;
Casale, TB .
INFLAMMATION RESEARCH, 1996, 45 (02) :89-95
[6]  
Carlson M, 1999, AM J GASTROENTEROL, V94, P1876
[7]   ACTIVATED EOSINOPHILS AND INTERLEUKIN-5 EXPRESSION IN EARLY RECURRENCE OF CROHNS-DISEASE [J].
DUBUCQUOI, S ;
JANIN, A ;
KLEIN, O ;
DESREUMAUX, P ;
QUANDALLE, P ;
CORTOT, A ;
CAPRON, M ;
COLOMBEL, JF .
GUT, 1995, 37 (02) :242-246
[8]   Treatment of ulcerative colitis with an engineered human anti-TNFα antibody CDP571 [J].
Evans, RC ;
Clarke, L ;
Heath, P ;
Stephens, S ;
Morris, AI ;
Rhodes, JM .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (06) :1031-1035
[9]   A 48-WELL MICRO CHEMOTAXIS ASSEMBLY FOR RAPID AND ACCURATE MEASUREMENT OF LEUKOCYTE MIGRATION [J].
FALK, W ;
GOODWIN, RH ;
LEONARD, EJ .
JOURNAL OF IMMUNOLOGICAL METHODS, 1980, 33 (03) :239-247
[10]   Corticosteroid effects on cytokines and chemokines [J].
Frieri, M .
ALLERGY AND ASTHMA PROCEEDINGS, 1999, 20 (03) :147-159